Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575809 | 0.85 | BRAF (0.65) | BRAFEGFRROCK1SYKMAP3K5 | |
| SCHEMBL29576177 | 0.84 | CDK4 (0.58) | BRAFEGFRMAP3K5RIPK2ACVR1 | |
| SCHEMBL29576906 | 0.81 | TAAR1 (0.52) | ROCK1MAP3K5ALDH1A1RECQLPKM | |
| SCHEMBL29575969 | 0.80 | BRAF (0.65) | BRAFEGFR | |
| SCHEMBL29370842 | 0.80 | BRAF (0.68) | BRAFEGFR | |
| SCHEMBL21835437 | 0.80 | BRAF (0.56) | BRAFEGFRROCK1SYKMAP3K5 | |
| SCHEMBL4030061 | 0.78 | MAP3K5 (0.55) | ROCK1SYKMAP3K5ALDH1A1RECQL | |
| SCHEMBL8891704 | 0.78 | NPY5R (0.67) | ALDH1A1RECQLNPC1PKMRAB9A | |
| SCHEMBL31381352 | 0.77 | MAP3K5 (0.60) | ROCK1SYKMAP3K5NPC1PKM | |
| SCHEMBL167891 | 0.77 | MAP3K5 (0.60) | ROCK1SYKMAP3K5NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | BRAF 61/4885EGFR 518/4885ROCK1 544/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | BRAF 61/4885EGFR 518/4885ROCK1 544/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | BRAF 61/4885EGFR 518/4885ROCK1 544/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | BRAF 61/4885EGFR 518/4885ROCK1 544/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | BRAF 61/4885EGFR 518/4885ROCK1 544/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | BRAF 1/4885EGFR 290/4885ROCK1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.